RICHTER SYNDROME
Clinical trials for RICHTER SYNDROME explained in plain language.
Never miss a new study
Get alerted when new RICHTER SYNDROME trials appear
Sign up with your email to follow new studies for RICHTER SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple therapy targets aggressive blood cancer in early trial
Disease control Recruiting nowThis study tests a combination of three treatments for Richter's transformation, an aggressive form of blood cancer. The approach uses the patient's own immune cells (liso-cel) plus two drugs (nivolumab and ibrutinib) to boost the immune system and block cancer growth. About 20 a…
Matched conditions: RICHTER SYNDROME
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New drug combo targets aggressive blood cancer in early trial
Disease control Recruiting nowThis early-phase study tests the safety and effectiveness of combining two drugs—zanubrutinib and odronextamab—in 23 adults with Richter's transformation, a fast-growing lymphoma that arises from chronic lymphocytic leukemia. Zanubrutinib blocks a protein that helps cancer grow, …
Matched conditions: RICHTER SYNDROME
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:13 UTC
-
New hope for richter syndrome: antibody-chemo combo targets aggressive lymphoma
Disease control Recruiting nowThis phase 2 trial tests a new drug called glofitamab combined with standard chemotherapy for people with untreated Richter syndrome, an aggressive lymphoma that can develop in patients with chronic lymphocytic leukemia. The study aims to see if this combination leads to more com…
Matched conditions: RICHTER SYNDROME
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated May 26, 2026 04:11 UTC
-
New hope for aggressive blood cancer: drug combo targets Richter's transformation
Disease control Recruiting nowThis study tests a new drug combination (polatuzumab vedotin plus chemotherapy) in 20 adults with Richter's transformation, an aggressive lymphoma that can develop from chronic lymphocytic leukemia. Participants receive up to six cycles of treatment and are monitored for safety a…
Matched conditions: RICHTER SYNDROME
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New combo therapy aims to keep lymphoma in check after transplant
Disease control Recruiting nowThis study is for people with certain types of B-cell or Hodgkin lymphoma. Participants first get a stem cell transplant using their own cells, then receive a targeted drug called polatuzumab vedotin every 3 weeks for up to 8 doses. The goal is to see if this approach is safe and…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: New York Medical College • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New cocktail targets deadly CLL complication
Disease control Recruiting nowThis study tests whether a combination of three drugs (acalabrutinib, venetoclax, and durvalumab) can help people with Richter transformation, a rare and aggressive lymphoma that develops from chronic lymphocytic leukemia (CLL). The drugs work by blocking cancer growth signals, t…
Matched conditions: RICHTER SYNDROME
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New hope for rare, aggressive blood cancer: drug duo enters trial
Disease control Recruiting nowThis study tests two drugs together for people with Richter transformation, a fast-growing lymphoma that can arise from chronic lymphocytic leukemia. The drugs aim to block cancer growth and help the immune system attack the cancer. About 32 adults who have not responded to or ca…
Matched conditions: RICHTER SYNDROME
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:39 UTC